BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36175647)

  • 21. Patterns of Recurrence after Resection for Pancreatic Neuroendocrine Tumors: Who, When, and Where?
    Marchegiani G; Landoni L; Andrianello S; Masini G; Cingarlini S; D'Onofrio M; De Robertis R; Davì M; Capelli P; Manfrin E; Amodio A; Paiella S; Malleo G; Damoli I; Miotto M; Bianchi B; Nessi C; Vivani E; Scarpa A; Salvia R; Bassi C
    Neuroendocrinology; 2019; 108(3):161-171. PubMed ID: 30481765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
    Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system--therapeutic strategies].
    Auernhammer CJ; Jauch KW; Hoffmann JN
    Zentralbl Chir; 2009 Sep; 134(5):410-7. PubMed ID: 19757340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors.
    Sposito C; Rossi RE; Monteleone M; Coppa J; Bongini M; Milione M; Bhoori S; Mazzaferro V
    Transplantation; 2021 Dec; 105(12):2579-2586. PubMed ID: 33908381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver Transplantation for Hepatitis B in Early Adulthood: Analysis of the United Network for Organ Sharing Database.
    Rifai G; Anani A; Hanouneh IA; Mohamad B; Matloob A; Lopez R; Zein NN; Alkhouri N
    Transplant Proc; 2016 Dec; 48(10):3362-3367. PubMed ID: 27931582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine Tumors: A Propensity-Score Matched Cohort Study.
    Kjaer J; Clancy TE; Thornell A; Andersson N; Hellman P; Crona J; Welin S; Sulciner M; Powell B; Brais L; Astone K; Baddoo W; Doherty G; Chan JA; Norlén O; Stålberg P
    Ann Surg Open; 2022 Mar; 3(1):e151. PubMed ID: 37600107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.
    Rindi G; Falconi M; Klersy C; Albarello L; Boninsegna L; Buchler MW; Capella C; Caplin M; Couvelard A; Doglioni C; Delle Fave G; Fischer L; Fusai G; de Herder WW; Jann H; Komminoth P; de Krijger RR; La Rosa S; Luong TV; Pape U; Perren A; Ruszniewski P; Scarpa A; Schmitt A; Solcia E; Wiedenmann B
    J Natl Cancer Inst; 2012 May; 104(10):764-77. PubMed ID: 22525418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Definitive locoregional therapy (LRT) versus bridging LRT and liver transplantation with wait-and-not-treat approach for very early stage hepatocellular carcinoma.
    Habibollahi P; Hunt S; Bitterman T; Gade TP; Soulen MC; Nadolski G
    Diagn Interv Radiol; 2018 Jul; 24(4):213-218. PubMed ID: 30091712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome.
    Panzuto F; Merola E; Rinzivillo M; Partelli S; Campana D; Iannicelli E; Pilozzi E; Mercantini P; Rossi M; Capurso G; Scarpa A; Cascinu S; Tomassetti P; Falconi M; Delle Fave G
    Pancreas; 2014 Mar; 43(2):212-8. PubMed ID: 24518498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
    Özaslan E; Demir S; Karaca H; Güven K
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria: liver transplantation versus locoregional therapy: A retrospective cohort study.
    Kim JH; Sinn DH; Gwak GY; Choi GS; Kim JM; Kwon CHD; Joh JW; Kim KY; Kim K; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Medicine (Baltimore); 2016 Aug; 95(35):e4735. PubMed ID: 27583916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
    Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
    JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
    Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
    JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metastases of pancreatic neuroendocrine tumor to the liver as extremely rare indication for liver transplantation in children. Case report and review of the literature.
    Ismail H; Broniszczak D; Markiewicz-Kijewska M; Ciopiński M; Teisseyre J; Kluge P; Dembowska-Bagińska B; Kościesza A; Socha P; Kaliciński P
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):e33-7. PubMed ID: 26850362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors.
    Chi W; Warner RRP; Chan DL; Singh S; Segelov E; Strosberg J; Wisnivesky J; Kim MK
    Pancreas; 2018 Mar; 47(3):321-325. PubMed ID: 29401168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.